Coordination of RNA cleavage with end modification and processing
Project Number3R35GM119550-04S1
Former Number5R35GM119550-04
Contact PI/Project LeaderHESSELBERTH, JAY R
Awardee OrganizationUNIVERSITY OF COLORADO DENVER
Description
Abstract Text
Abstract
Programmed or unintentional RNA cleavage leads to "dirty" RNA 5´ and 3´ ends
that are remodeled by RNA end modification enzymes. The products of RNA end
modification are substrates for RNA processing activities that catalyze RNA
repair, decay or stabilization. Because some processing enzymes recognize
different modified termini, RNA end modification enzymes could promote some
processing steps while inhibiting others. Conversely, RNA processing enzymes
that catalyze different reactions might recognize – and compete for – substrates
with the same end modification to control the outcome of RNA cleavage. These
different scenarios could potentially be used to regulate the outcome of RNA
cleavage, but we know very little about the roles of RNA end modification during
RNA processing. We discovered that RNA end modification by the RNA 5´-
kinase activity of the yeast tRNA ligase Trl1 is important to regulate the unfolded
protein response by phosphorylating RNA intermediates during unintentional
UPR activation to facilitate their turnover by 5´→3´ decay, and that Trl1 RNA 5´-
kinase activity mediates the turnover of mRNA fragments created by co-
translational “no-go” mRNA decay. The human RNA 5´-kinase enzyme Clp1 has
an important role in neuronal metabolism and differentiation, but we do not know
the substrates of Clp1 and so it is not clear how dysfunction in RNA 5´-kinase
activity leads to disease. Our discovery that Trl1 5´-kinase activity mediates the
decay of mRNA cleavage fragments also begs the question of whether the Trl1
ligase can also repair RNAs, but only a few examples of RNA repair are known.
To address these issues, we will focus on the following questions: 1. What are
the substrates of the human Clp1 RNA 5´-kinase?; 2. How do RNA end
modification and processing regulate the unfolded protein response?; 3. How are
the products of no-go mRNA decay created, and what are its physiological
substrates?; 4. Is RNA repair restricted to specific substrates, or does it act on
other damaged RNAs? The outcomes of these studies will be an improved
understanding of how RNA end modification is used after RNA cleavage to
mediate RNA processing, and these insights may inform our understanding of
how dysfunction in RNA end modification underlies human disease.
Public Health Relevance Statement
Narrative
During stress and normal growth, cells initiate programmed cleavage of RNAs by
endonucleases to facilitate RNA processing. Several RNA end modification
enzymes act on RNA cleavage products and have important roles in neuronal
metabolism and differentiation, but we do not understand how the dysregulation
RNA end modification causes disease. We will use new DNA sequencing-based
methods as wells as genetic and biochemical approaches in yeast and human
cells to address several unanswered questions about the roles of RNA end
modification enzymes in cells, which will hopefully improve our understanding of
their roles in RNA processing in cells, and may lead to new insights into their
roles in human disease.
No Sub Projects information available for 3R35GM119550-04S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R35GM119550-04S1
Patents
No Patents information available for 3R35GM119550-04S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R35GM119550-04S1
Clinical Studies
No Clinical Studies information available for 3R35GM119550-04S1
News and More
Related News Releases
No news release information available for 3R35GM119550-04S1
History
No Historical information available for 3R35GM119550-04S1
Similar Projects
No Similar Projects information available for 3R35GM119550-04S1